TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: maximum tolerated doses of capecitabine and oxaliplatin
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of identifying wounds with moderate/heavy bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Clear/Almost Clear of Plaque Psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of sex hormone levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Composite of BARC Types 2, 3, and 5 bleeding or vascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in career maturity inventory--attitude scale (CMI-AS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: number of pointing error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measure of reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of right responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cytogenetic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of postpyloric placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach intragastric and postpyloric position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of insertion, handling and image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Total Lean Body Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Skeletal Muscle Strength by 1-RM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of participants without a relapse
Endpoint domain: Mortality/survival
Primary endpoint: Galveston Orientation and Amnesia Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinical Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Total Exercise Duration on the Treadmill Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Itraconazole Levels and Hydroxyitraconazole Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thigh Circumference Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Inner Thigh Skin Fold Thickness Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number Of Participants With Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Development of tissue antibodies towards donor cells
Endpoint domain: Adverse events/effects
Primary endpoint: Postpartum hemorrhage after cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of Participants With PCR-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vineland Adaptive Behavioral Scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MMP-9 and SIRT-1 levels (ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Pain Relief Over 6 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fluid Cognition Composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Executive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Processing Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Episodic Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time from treatment start to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean Change in Agitation/Aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In hospital Mortality
Endpoint domain: Mortality/survival
Primary endpoint: AC/A Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional intimacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical intimacy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Upper limb thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Humoral immune response measured by HI antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of Dose limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete clinical remission of the warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of Asthma Control Test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of olmesartan in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of olmesartan in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Demonstrating a Decrease in the Growth Factor Signature (GFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change/maintenance in muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Linear wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Fold-rise in 0657n-specific IgG Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Adverse Experiences (AE)/Serious Adverse Experiences (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Work stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of COVID-19 symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Toxicity and efficacy trade-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of daily urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Social cognition assessment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Score on ADHD Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neutrophil/lymphocyte ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: uric acid values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage reduction in ulcer surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in polysomnographically-derived wake after sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean sleep latency test-derived mean sleep latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration of motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasopressor- and Mechanical Ventilator-free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved a Second Decline in PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Absence of irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic testing trunk flexion-extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isokinetic testing hip abduction-adduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Number of Dry Nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Voids Per Night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quantity of Wetness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QOL Measures Using the KIDS Screen Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oxygenation (PO2/FIO2 ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of responders showing improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gut transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gut contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of life for urinary
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Clinically Significant Hematology Laboratory Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Clinically Significant Electrocardiogram Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Clinically Significant Vital Signs Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Clinically Significant Serum Chemistry Laboratory Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Malaria incidence density
Endpoint domain: Mortality/survival
Primary endpoint: Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Preoperative copeptin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory block level to ice equal to or higher than T6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of normal 24-hour average testosterone and sperm concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC0-T apixaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Limb Tremor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Biodegradation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production of Reactive Oxygen Species (ROS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Outcome of factor replacement treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aHAV antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of left ventricular eject factor (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regional Cerebral perfusion during mood induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: morning urine protein/creatinine >0.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reported sleep duration (hours)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Progression of respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of major bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of patients with positive stool analysis for cryptosporidium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Hospitalizations for COPD Exacerbation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants Reporting Clinically Significant MRI Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean sleep latency from the Multiple Sleep Latency Test (MSLT)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Clinical Global Impression of Change (CGI-C) ratings for ES
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GRS (Global Rating Scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bioavailability of GLPG0259
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton anxiety scale (HAM-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hamilton depression scale (HAM-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time needed for MEP amplitude to return to Baseline after TBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Basal Insulin Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Side effects of proton radiation therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Pathological fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Baseline Corrected Maximum Observed Plasma Concentration (Cmax[Adj]) of Levothyroxine Sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline Corrected Area Under The Plasma Concentration-time Curve From Time Zero to 72 Hours (AUC0-72 [Adj]) of Levothyroxine Sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overbite measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the Cognitive subscale of the Alzheimer's Disease Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Preparedness to Make the Contralateral Prophylactic Mastectomy Decisions
Endpoint domain: Life impact
Endpoint subdomain: Decision-making
Primary endpoint: Change in TSI-2 following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TSCC following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine administration within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective treatment of pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Household contact screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Medication emergent side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Delivery rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Displacement of COP (center of pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of malocclusion requiring early orthodontic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMJ condyle-disc and glenoid fossa changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eminence angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sagittal disc position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronal disc position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Suspected Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Attendance at the first medical visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Attendance at the second medical visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Distance traveled at the 6-minute walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Complete Remission Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physician's assessment of efficacy and tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient's condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Treatment Completion Rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of incidence of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: cough threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in reduced glutathione in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in protein carbonyls in red blood cells and serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in C-reactive protein in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with eradicated varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post-lumbar puncture headache
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with clinically relevant changes in vital functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with clinically relevant changes in electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PDE4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative opioid (oxycodone) consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients With Disease Progression (Intention-to-treat Population)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Disease Progression (Per-protocol Population)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal BMI at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant weight at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant body fat measured using an EchoMRI body composition analyzer at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Salivary Cortisol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Work Ability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cognitive benefit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lung toxicity (pneumonitis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in global cognitive scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in domain averages
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 3-year Disease-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Objective Response Rate (PR + CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Vital Sign Parameter Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage heavy drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with co-infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Bone Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone Turnover P1NP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Turnover Beta Crosslaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Appearance of islet cell autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response Benefit (Complete Response or Partial Response or Stable Disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: plasma homocysteine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plasma folate acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes